Answers are grounded in this paper and cite their sources.
In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).
No takes yet. Share an insight, caveat, or question.
Wilding et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: